CTNNB1, catenin beta 1, 1499

N. diseases: 1368; N. variants: 68
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer. 31193124 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. 22232518 2012
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our study identifies activated Wnt signalling to be a marker for precursor lesions of OC and successfully develops a mouse model that mimics the earliest events in pathogenesis of OC by constitutively activating βcatenin. 27588493 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE Further, the expression of SOX9, β-catenin, and c-Myc in OC tissues was upregulated and inversely correlated with miR-34c expression, indicating that rescuing miR-34c expression, thus to inhibit SOX9, β-catenin, and c-Myc expression presents a promising strategy of reducing the chemoresistance of the OC cell to DDP. 30537410 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer. 28090074 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Collectively, these data indicated that β-catenin is involved in Twist2-induced EMT in ovarian cancer. 24244294 2013
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 GeneticVariation disease BEFREE We studied nine single nucleotide polymorphisms (SNPs) located in CTNNB1 (β-catenin) [rs4533622, rs2953], APC (rs11954856, rs351771, rs459552), and AXIN2 (rs4074947, rs7224837, rs3923087, rs2240308) in women with ovarian cancer without BRCA1/BRCA2 mutations (n = 228) and controls (n = 282). 24078348 2014
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE These results suggested that miR-214 may serve as a tumor suppressor of ovarian cancer by targeting the β-catenin pathway. 29486472 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. 26341496 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE JRK is a positive regulator of β-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. 26455321 2016
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 GeneticVariation disease BEFREE In search of this transformation mechanism in human cancer cells, we identified breast and ovarian tumor lines with upregulation of the uncomplexed transcriptionally active form of beta-catenin without mutations afflicting downstream components. 15542433 2004
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE These results uncover β-catenin as a critical factor in promoting ovarian cancer aggressiveness and a new mechanism linking between β-catenin and miRNA downregulation underlying this process. 28650464 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE A recent report describing the presence of beta-catenin mutations in endometrioid ovarian cancer suggested that the TCF/beta-catenin pathway may be generally activated in ovarian cancer. 10739697 2000
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Thus, β-catenin could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer. 25211326 2015
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin. 31653698 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE β-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model. 24954508 2015
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Taken together, this study showed that Annexin A2 inhibition suppresses proliferation and invasion in ovarian cancer via β-catenin/EMT, proposing the potential role of Annexin A2 in the prevention and treatment of ovarian cancer. 28440436 2017
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE In addition, we have determined that the cadherin-associated protein, known as beta-catenin, is expressed in normal peritoneum, ovarian tumors and malignant cell effusions obtained from women with Stage I or Stage II cancer. 12800191 2003
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 GeneticVariation disease BEFREE This revealed 10/63 (16%) endometrioid ovarian tumours with activating mutations of the beta-catenin gene. 10417756 1999
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. 15911235 2005
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 GeneticVariation disease BEFREE Nuclear immunoreactivities for beta -catenin and CTNNB1 mutations were restricted to independent uterine and ovarian tumors and were absent in all of the metastatic tumors, providing direct evidence for a divergence of molecular oncogenetic mechanisms in the subset of synchronous endometrioid carcinomas. 16021566 2005
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 AlteredExpression disease BEFREE Nucleus and/or cytoplasma of β-catenin expression might be associated with tumor progression and could be a possible potential predictive factor of poor prognosis in OC patients. 30103006 2018
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. 16479254 2006
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 Biomarker disease BEFREE Our work also provides a proper understanding on the regulation of Wnt/β-catenin pathway in ovarian cancer. 30572097 2019
CUI: C0919267
Disease: ovarian neoplasm
ovarian neoplasm
0.900 GeneticVariation disease BEFREE Oncogenic activation of the Wnt signaling pathway is common in cancers, but mutation of beta-catenin in ovarian cancer is rare. 19957335 2010